Medtronic enrols US patients in ENDEAVOR IV trial:
This article was originally published in Clinica
Medtronic has begun enrolling patients into ENDEAVOR IV, the final phase of a clinical trial programme that will be used to support a US marketing application for its ABT-578-eluting stent, Endeavor. ENDEAVOR IV is a randomised, single-blind trial comparing Endeavor's safety and efficacy with Boston Scientific's market leading drug-eluting stent, Taxus, a paclitaxel-coated device. The study will include around 1,548 patients and will be performed at around 80 centres in the US and Canada. Its primary endpoint is target vessel failure at nine months.